‘PfizerKline’ is just a speculation: GSK

Mr Annaswamy Vaidheesh, VP, South Asia & MD, India, GlaxoSmithKline India (GSK) told BioSpectrum that the concept of PfizerKline is just a speculation.


(Photo Courtesy: www.wideanglefilms.com)

GSK today held its groundbreaking ceremony for its upcoming new manufacturing pharma facility near Bangalore, in Kolar, with an investment of Rs 1000 crore (£100 million).

For this, the Government of Karnataka has allotted 50 acres of Karnataka Industrial Area Development Board (KIADB) land at Vemgal Industrial Area located in Kolar, 50km to the east of Bangalore.

It is expected to manufacture 8 billion tablets and 1 billion capsules relating to gastroenterology and anti-inflammatory medicines primarily for the Indian market.

The first production batches will begin by the end of 2016.

Initially the facility will supply solid dose formulation products.

The factory will employ 300 professionals, and Mr James Hogg, who is the Indian head of the GSK pharma factory, will also be in-charge of the project.


Previous 1 3 4 Next

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email